Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Other Operating Expenses (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of Other Operating Expenses readings, the most recent being $34.6 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 181.3% to $34.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $554.5 million, a 42.54% increase, with the full-year FY2025 number at $69.5 million, up 49.46% from a year prior.
  • Other Operating Expenses hit $34.6 million in Q4 2025 for Neurocrine Biosciences, up from $14.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $265.0 million in Q1 2025 to a low of $2.9 million in Q1 2021.
  • Median Other Operating Expenses over the past 5 years was $24.4 million (2025), compared with a mean of $77.9 million.
  • Biggest five-year swings in Other Operating Expenses: surged 3500.0% in 2021 and later crashed 93.33% in 2022.
  • Neurocrine Biosciences' Other Operating Expenses stood at $104.4 million in 2021, then plummeted by 92.62% to $7.7 million in 2022, then grew by 10.39% to $8.5 million in 2023, then surged by 44.71% to $12.3 million in 2024, then soared by 181.3% to $34.6 million in 2025.
  • The last three reported values for Other Operating Expenses were $34.6 million (Q4 2025), $14.3 million (Q3 2025), and $240.6 million (Q2 2025) per Business Quant data.